Evidence map›Paper›PMID 38347143›Full record

ArticleNature cancer2024

Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities.

Yi-Zhou Jiang, Ding Ma, Xi Jin, Yi Xiao, Ying Yu, Jinxiu Shi, Yi-Fan Zhou, Tong Fu, Cai-Jin Lin, Lei-Jie Dai and 26 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Yi-Zhou Jiang *Key Laboratory of Breast Cancer, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. yizhoujiang@fudan.edu.cn.ORCID http://orcid.org/0000-0003-3699-2630
Ding Ma *Key Laboratory of Breast Cancer, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID http://orcid.org/0009-0000-4890-6424
Xi Jin *Key Laboratory of Breast Cancer, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yi Xiao *Key Laboratory of Breast Cancer, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Ying Yu *State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute and Shanghai Cancer Center, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-4084-908X
Jinxiu Shi *Shanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), Shanghai, China.
Yi-Fan ZhouKey Laboratory of Breast Cancer, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Tong FuKey Laboratory of Breast Cancer, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Cai-Jin LinKey Laboratory of Breast Cancer, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Lei-Jie DaiKey Laboratory of Breast Cancer, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-8539-8921
Cheng-Lin LiuKey Laboratory of Breast Cancer, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Shen ZhaoKey Laboratory of Breast Cancer, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Guan-Hua SuKey Laboratory of Breast Cancer, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Wanwan HouState Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute and Shanghai Cancer Center, Fudan University, Shanghai, China.
Yaqing LiuState Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute and Shanghai Cancer Center, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0001-9356-9164
Qingwang ChenState Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute and Shanghai Cancer Center, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-7191-5801
Jingcheng YangState Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute and Shanghai Cancer Center, Fudan University, Shanghai, China.
Naixin ZhangState Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute and Shanghai Cancer Center, Fudan University, Shanghai, China.
Wen-Juan ZhangKey Laboratory of Breast Cancer, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Wei LiuWestlake Omics (Hangzhou) Biotechnology, Hangzhou, China.
Weigang GeWestlake Omics (Hangzhou) Biotechnology, Hangzhou, China.
Wen-Tao YangDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID http://orcid.org/0000-0001-7712-822X
Chao YouDepartment of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yajia GuDepartment of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
Virginia KaklamaniDivision Haematology/Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
François BertucciPredictive Oncology Laboratory and Department of Medical Oncology, CRCM, Institut Paoli-Calmettes, Inserm UMR1068, CNRS UMR7258, Aix-Marseille Université, Marseille, France.ORCID http://orcid.org/0000-0002-0157-0959
Claire VerschraegenThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Anneleen DaemenDepartment of Bioinformatics and Computational Biology, Genentech, South San Francisco, CA, USA.
Nakul M ShahDepartment of Genetics, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-1775-2279
Ting WangDepartment of Genetics, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-6800-242X
Tiannan GuoWestlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, China.ORCID http://orcid.org/0000-0003-3869-7651
Leming ShiState Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute and Shanghai Cancer Center, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-2981-4150
Charles M PerouLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-9827-2247
Yuanting ZhengState Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute and Shanghai Cancer Center, Fudan University, Shanghai, China. zhengyuanting@fudan.edu.cn.ORCID http://orcid.org/0000-0003-4480-8303
Wei HuangShanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), Shanghai, China. huangwei@chgc.sh.cn.ORCID http://orcid.org/0000-0001-8047-3286
Zhi-Ming ShaoKey Laboratory of Breast Cancer, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. zhimingshao@fudan.edu.cn.ORCID http://orcid.org/0000-0002-4503-148X

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82272704National Natural Science Foundation of China (National Science Foundation of China) 82272822National Natural Science Foundation of China (National Science Foundation of China) 92159301, 82341003, 91959207
6 · The paper itself

Abstract

Molecular profiling guides precision treatment of breast cancer; however, Asian patients are underrepresented in publicly available large-scale studies. We established a comprehensive multiomics cohort of 773 Chinese patients with breast cancer and systematically analyzed their genomic, transcriptomic, proteomic, metabolomic, radiomic and digital pathology characteristics. Here we show that compared to breast cancers in white individuals, Asian individuals had more targetable AKT1 mutations. Integrated analysis revealed a higher proportion of HER2-enriched subtype and correspondingly more frequent ERBB2 amplification and higher HER2 protein abundance in the Chinese HR

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesAdultBiomarkers, TumorChinaEast Asian PeopleFemaleFerroptosisGene Expression ProfilingHumansMetabolomicsMiddle AgedMutationProteomicsProto-Oncogene Proteins c-aktTranscriptomeBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesProto-Oncogene Proteins c-akt

Identifiers

PMID38347143

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.